China Pharma Shares Owned By Insiders vs. Revenue
| CPHI Stock | USD 0.20 0.01 5.26% |
For China Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of China Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well China Pharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between China Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of China Pharma Holdings over time as well as its relative position and ranking within its peers.
China |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
China Pharma Holdings Revenue vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining China Pharma's current stock value. Our valuation model uses many indicators to compare China Pharma value to that of its competitors to determine the firm's financial worth. China Pharma Holdings is number one stock in shares owned by insiders category among its peers. It is rated third in revenue category among its peers totaling about 136,739 of Revenue per Shares Owned By Insiders. As of now, China Pharma's Total Revenue is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Pharma's earnings, one of the primary drivers of an investment's value.China Revenue vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
China Pharma |
| = | 51.27 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
China Pharma |
| = | 7.01 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
China Revenue vs Competition
China Pharma Holdings is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 2.68 Billion. China Pharma adds roughly 7.01 Million in revenue claiming only tiny portion of equities under Health Care industry.
China Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in China Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, China Pharma will eventually generate negative long term returns. The profitability progress is the general direction of China Pharma's change in net profit over the period of time. It can combine multiple indicators of China Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 11.5 M | 9.9 M | |
| Operating Income | -2.8 M | -2.6 M | |
| Income Before Tax | -3.1 M | -2.9 M | |
| Total Other Income Expense Net | -327 K | -343.3 K | |
| Net Loss | -3.1 M | -2.9 M | |
| Income Tax Expense | (4.00) | (3.80) | |
| Net Loss | -3.1 M | -3.2 M | |
| Net Loss | -3.1 M | -3.3 M | |
| Non Operating Income Net Other | 5.1 K | 4.9 K | |
| Interest Income | 5.1 K | 4.8 K | |
| Net Interest Income | -374.4 K | -393.2 K | |
| Change To Netincome | -276 K | -262.2 K | |
| Net Loss | (0.91) | (0.86) | |
| Income Quality | 0.23 | 0.24 | |
| Net Income Per E B T | 2.96 | 3.11 |
China Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on China Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of China Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the China Pharma's important profitability drivers and their relationship over time.
Use China Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will appreciate offsetting losses from the drop in the long position's value.China Pharma Pair Trading
China Pharma Holdings Pair Trading Analysis
The ability to find closely correlated positions to China Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Pharma Holdings to buy it.
The correlation of China Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Pharma Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your China Pharma position
In addition to having China Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
To fully project China Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of China Pharma Holdings at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include China Pharma's income statement, its balance sheet, and the statement of cash flows.